Kadcyla Reproduces Hopes for Breast Cancer Treatment

“Kadcyla doubles the delay in the disease level progression for advanced metastatic breast cancer patients, compared to Conventional Treatment”, Says RNCOS.


Noida, UP -- (SBWIRE) -- 01/08/2015 -- According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", the rise of Kadcyla represents an entirely new way to treat HER2 positive breast cancer. In one of the Phase III trials, the drug delivered a 32% reduction in death risk in comparison to a standard care of treatment. Even the molecule has doubled the delay in disease progression for advanced breast cancer patients. Roche Genentech Blockbuster ADC poses a revolutionary treatment option for breast cancer in the US and European Markets.

As per American Cancer Society, there were 2,829,041 Americans with breast cancer and 72,269 with gastric cancer in 2012. Similarly, in Europe, 1,837,855 people were suffering with breast cancer and 117,903 were with gastric cancer in 2012. As Kadcyla gets tested for late stage clinical trials for early breast cancer as well as gastric cancer, the successful completion of these trials would render a potential population of 2.9 Million and 1.95 Million in US and Europe, respectively. Clinical Studies have shown that it proves to be more effective than other therapies such as Perjeta and GSK's Tykerb. Following these developments, market for Kadcyla has huge growth potential.

This report is spread over 60 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.

The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.

At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.